Linker Information
General Information of This Linker
| Linker ID |
LIN0ISQWW
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Val-Cit-(PEG24) linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
S227928 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients had R/R AML/MDS-AML/CMML (WHO/ICC 2022), ECOG ≤2, leukocytes <10×10<sup>9</sup>/L (hydroxycarbamide permitted), and adequate renal/hepatic function. Exclusions included pregnancy, uncontrolled infections (HBV/HCV/HIV under strict criteria), QTc prolongation (>450ms males/>470ms females), active CNS involvement, recent allogeneic SCT (<3 months), dual CYP3A4/CYP2C8 inhibitors (Arm A), or P-gp/BCRP interactions (Arms B/expansion). Prior anticancer therapy required a 2-week/5-half-life washout (28 days for biologics).
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06563804 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
|
||||
| Primary Endpoint |
The dose-escalation phase evaluated DLTs during Cycle 1 (28 days) and tracked AE/SAE incidence over ~3.5 years, including dose adjustments/discontinuations. CR was assessed in dose expansion (~4 years).
|
||||
| Other Endpoint |
PK parameters (Cmax, Tmax, AUC, plasma profiles) for S227928 components (total mAb, unconjugated S64315) and venetoclax (Arm B/dose expansion) were analyzed over ~3.5 years. Efficacy outcomes (CR/CRi/CRh/MLFS/PR/ORR/DOR/PFS/OS/EFS) and transfusion independence were assessed in R/R AML/MDS-AML/CMML patients over ~4 years, with cohort-specific analyses (e.g., CRL/HI for CMML). ADA against S227928 was monitored.
Click to Show/Hide
|
||||
References